# Diabetes Research Hub — Automated Iteration Report
**Date:** 2026-04-21 (Tuesday)
**Commit:** be682ef

## Work Queue Processed (6 items)

### 1. Vetted 15 papers (0 flagged)
**In-library (PMID verified against local abstracts):**
- 25772230 — Racial/ethnic disparities in T2D care (Curr Med Res Opin 2015)
- 25834231 — Proglucagon peptides physiology (Physiol Rev 2015)
- 25940230 — Mediterranean Diet / PREDIMED (Prog Cardiovasc Dis 2015)
- 26106223 — GCK-MODY recognition & management (Diabetes Care 2015)
- 26322160 — Magnesium and T2D (World J Diabetes 2015)
- 26378978 — EMPA-REG OUTCOME (NEJM 2015)
- 26404926 — JDRF/ADA staging presymptomatic T1D scientific statement (Diabetes Care 2015)
- 26590418 — Personalized nutrition by glycemic response prediction / Zeevi (Cell 2015)
- 26656660 — TNF biology and therapeutic strategies (Nat Rev Rheumatol 2016)
- 26784127 — CGM review (Diabetes Technol Ther 2016)

**Not in local library — PMIDs verified via NCBI esummary API (recent 2026 pubs, peripheral relevance):**
- 41967038 — Vit D + catechin, TGF-β1/SMAD, diabetic cardiomyopathy (J Pharm Pharmacol, Apr 2026)
- 41958082 — Capparis Spinosa + glutamine, Nrf2/HO-1, diabetic wound healing (Chem Biodivers 2026)
- 41923724 — PARP inhibitors + anti-VEGF for diabetic retinopathy (Rev Cardiovasc Med 2026)
- 41923440 — Network pharmacology + gut microbiome, hydroxysafflor yellow A (J Diabetes Res 2026)
- 41906653 — Hydrogen-enriched hyaluronic acid, diabetic foot ulcer (J Diabetes, Apr 2026)

All 15 PMIDs are real; titles and journals are consistent with the corpus's recorded metadata. No red flags, no fabrication. Non-library PMIDs are marked for library indexing in a future pass.

### 2. Gap 15 — SGLT2 Inhibitors × Personalized Nutrition (BRONZE retained)
New context since 2026-04-16 audit: FDA approved first generic dapagliflozin (2026-04-07), NICE 2026 final guidance recommends SGLT2i+metformin personalized first-line, and npj Metabolic Health 2025 (PMC12217734) frames SGLT2i precision medicine via biomarkers/renal function/AI/microbiome. None of this is *dietary/nutritional* personalization. Direct SGLT2i × personalized-nutrition intersection remains absent. Retain BRONZE with `promotion_candidate=true`.

### 3. Gap 4 — Islet Transplant × Personalized Nutrition (SILVER retained)
Post-transplant nutrition guidance (PMID 33002260, PMID 23769100) is generic post-surgical dietary advice, not genomic/microbiome-driven personalization. 2025 Frontiers Transplantation 1522409 post-BLA review does not bridge to personalized nutrition. Direct intersection remains zero.

### 4. Gap 5 — Islet Transplant × Drug Repurposing (SILVER retained)
Frontiers Transplantation 2025 1514956 ("From Edmonton to Lantidra") mentions repurposed immunomodulators in encapsulation devices but no systematic repurposing workflow targeting islet transplant outcomes. BioDrugs 2025 (PMC11906537) and Sana hypoimmune NEJM 2025 follow the same pattern. No systematic intersection yet.

### 5. New path validated: GLP1_RA → T1D (PARTIALLY_VALIDATED, MEDIUM confidence)
Meta-analyses of GLP-1 analogues as adjunctive therapy in T1D (PubMed 37561012, 24 studies n=3,377; Hormones 2025 10.1007/s42000-025-00704-9) show modest HbA1c reduction, weight loss, and reduced total daily insulin. Subgroup analyses show larger effect in C-peptide-detectable patients — suggestive but not proof of beta-cell preservation. 2025 Frontiers Pharmacology 10.3389/fphar.2025.1610512 explicitly states large-RCT-grade beta-cell preservation evidence in newly diagnosed T1D **remains to be determined**. Path stored with explicit caveats to prevent overstatement.

### 6. Credibility sweep + pipeline rebuild
- No PMIDs > 42,000,000 (no fabricated PMIDs).
- No prohibited absolutist claims ("zero SAEs", "zero rejection", "curative", "achieves cure") outside the verification script itself.
- `run_quality_improvements.py` produced 39 `[OK]`/`Completed` markers, 0 errors.
- 260 PMIDs verified via PubMed API (Not Found: 0, API Errors: 0).
- Dashboards regenerated at 08:14 UTC.

## State Snapshot
- Total papers tracked: 267
- Vetted: 116 (↑15), Flagged: 6, Unvetted: 145 (↓15)
- Paths: 79 (added GLP1_RA → T1D)
- Work queue: 9 items (reprioritized for next run)

## Next Run Priorities
1. Vet next batch of ~15 papers (~145 unvetted remaining)
2. Audit Gap 11 (Treg/CAR-T × Personalized Nutr)
3. Validate verapamil → T1D path follow-up (CLVer extension)
4. PubMed search: Abata ABA-201 CAR-Treg T1D first-in-human readout
5. PubMed search: DIAMYD / DIAGNODE Extension long-term follow-up

## Git
- Committed locally as `be682ef` on `main` (40 files changed, +14,678 / -15,549 lines).
- Push deferred to host-side `refresh.ps1` (sandbox has no GitHub credentials).
